Simulations Plus (NASDAQ:SLP) Announces Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Simulations Plus (NASDAQ:SLP) announced its quarterly earnings data on Sunday. The technology company reported $0.12 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.11 by $0.01, MarketWatch Earnings reports. Simulations Plus had a return on equity of 24.44% and a net margin of 22.96%.

Shares of Simulations Plus stock traded down $8.28 on Tuesday, hitting $71.05. 23,687 shares of the company traded hands, compared to its average volume of 287,831. The company has a 50-day moving average price of $65.06 and a 200 day moving average price of $65.43. Simulations Plus has a 12-month low of $26.00 and a 12-month high of $83.78. The company has a market cap of $1.42 billion, a PE ratio of 152.38, a PEG ratio of 7.63 and a beta of -0.17.

In related news, CEO Shawn Oconnor sold 5,500 shares of the company’s stock in a transaction on Monday, November 23rd. The shares were sold at an average price of $56.25, for a total value of $309,375.00. Following the completion of the sale, the chief executive officer now directly owns 6,381 shares in the company, valued at $358,931.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Walter S. Woltosz sold 24,000 shares of the company’s stock in a transaction on Wednesday, December 23rd. The stock was sold at an average price of $72.71, for a total transaction of $1,745,040.00. Following the completion of the sale, the director now owns 4,659,614 shares of the company’s stock, valued at $338,800,533.94. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 64,881 shares of company stock worth $4,347,992. 31.57% of the stock is currently owned by corporate insiders.

Several equities analysts have recently issued reports on the company. TheStreet upgraded Simulations Plus from a “c+” rating to a “b” rating in a research report on Friday. Raymond James began coverage on shares of Simulations Plus in a research note on Friday, October 16th. They set an “outperform” rating and a $95.00 target price on the stock. Oppenheimer boosted their target price on shares of Simulations Plus from $79.00 to $85.00 in a research note on Tuesday. Zacks Investment Research downgraded shares of Simulations Plus from a “hold” rating to a “sell” rating in a research note on Thursday, November 19th. Finally, Craig Hallum downgraded shares of Simulations Plus from a “buy” rating to a “hold” rating in a research note on Tuesday. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $81.60.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments.

Read More: Risk Tolerance and Your Investment Decisions

Earnings History for Simulations Plus (NASDAQ:SLP)

Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.